Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PROF
SELLREMOVEProfound Medical Corp. · Healthcare · Canada · $251M · Avg Vol: $368K/d
Profound Medical Corp is an early-stage medical device company. It is currently unprofitable and faces high adoption hurdles for its TULSA-PRO system, making it too speculative for our concentrated quality portfolio.
COMPANY DESCRIPTION
Profound Medical Corp. develops and markets TULSA-PRO, a medical device platform combining real-time MRI guidance with robotically controlled therapeutic ultrasound for prostate disease treatment, and also has a neuroablation platform, Sonalleve. It offers a unique, minimally invasive treatment by integrating MRI and therapeutic ultrasound, providing precision and real-time monitoring, which creates a significant competitive advantage. Profound Medical is a medical technology innovator focused on image-guided therapeutic ultrasound, providing advanced treatment options.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 6.7M | 7.2M | 10.7M | 16.1M | 34.1% |
| EPS | — | -1.38 | -1.34 | -1.12 | -1.41 | — |
| Shares | — | 20.9M | 21.4M | 30.0M | 36.3M | +73.8% |
| Debt | — | 8.2M | 7.9M | 5.1M | 4.7M | -17.0% |
| Equity | — | 52.0M | 31.2M | 60.4M | 66.4M | 8.5% |
| Op CF | — | -25.8M | -22.6M | -23.5M | -38.2M | — |
| Inv CF | -0.6M | 0 | — | 0 | -0.2M | — |
| Fin CF | — | 7.0M | 1.8M | 54.7M | 41.1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PROF are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PROF | Profound Medical Corp.(you) | $251M | 24 | SELL |
| BLO.CN | Cannabix Technologies Inc. | $58M | 11 | STRONG SELL |
| TLT.V | Theralase Technologies Inc. | $45M | 13 | STRONG SELL |
| PINK.V | Perimeter Medical Imaging AI, Inc. | $30M | 9 | STRONG SELL |
| HITI | High Tide Inc. | $205M | 25 | SELL |
| EDT.TO | Spectral Medical Inc. | $282M | 28 | SELL |
| EPRX | Eupraxia Pharmaceuticals Inc. | $425M | 25 | SELL |
| ACB.TO | Aurora Cannabis Inc. | $180M | 30 | SELL |
| CRDL.TO | Cardiol Therapeutics Inc. | $123M | 22 | SELL |
| WEED.TO | Canopy Growth Corporation | $501M | 21 | SELL |
Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 32.9%